evipedia.ai
← Back

Indole-3-Carbinol for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: I3C, Indole-3-Methanol, Indol-3-ylmethanol, 3-Indolylmethanol, 3-Hydroxymethylindole, Indolcarbinol, Indinol

Motivation

Indole-3-carbinol is a compound that forms in cabbage, broccoli, kale and other members of the cabbage family when their leaves are chopped or chewed. Once ingested, stomach acid rearranges it into a family of related molecules that attach to proteins controlling how the body processes hormones and foreign chemicals. Most of the interest rests on one downstream effect: it changes the route by which the body breaks estrogen down.

Cabbage-family vegetables have been tied to lower cancer rates for decades, and this compound became a leading candidate for why. From the 1990s onward it was concentrated into capsules and tested in women with precancerous changes of the cervix and vulva, and in people with repeated wart-like growths in the airway. Animal work pointed the other way in some settings, where the same compound encouraged tumor growth when it was given after a cancer-causing chemical rather than before.

This review examines what the human and animal evidence shows about concentrated indole-3-carbinol, which of its effects have been measured as clinical outcomes rather than laboratory markers, what is known about its safety and its influence on the clearance of other medications, and how it has been dosed.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews, expert commentary and narrative reviews that cover indole-3-carbinol (I3C) and its chemistry, clinical record and unresolved safety questions in depth.

Content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io could not be included: the FoundMyFitness material is sulforaphane-centered or members-only, the two Chris Kresser hits mention I3C only in passing, and Peter Attia, Andrew Huberman and Lifespan.io return no matching content at all.

Grokipedia

  • Indole-3-carbinol

    A structured reference entry covering the compound’s chemistry, its glucobrassicin origin and acid conversion to DIM (3,3’-diindolylmethane, the metabolite that reaches the bloodstream), and the glucobrassicin content of cruciferous vegetables against typical supplement doses.

Examine

  • DIM

    Examine’s dedicated page for DIM, the metabolite that actually reaches the bloodstream after I3C is ingested, with its position on dose-dependent effects on aromatase, the enzyme converting testosterone into estrogen.

No Examine article exists for indole-3-carbinol itself: a direct site search for the compound returns no results, and the page above is Examine’s dedicated entry for its principal metabolite rather than for I3C.

ConsumerLab

  • I3C From Broccoli & Cancer Risk

    An independent testing organization’s assessment of whether the supplement form delivers the cancer-risk reduction associated with the vegetables it comes from.

Systematic Reviews

The systematic reviews and meta-analyses below cover both the claimed clinical benefit of I3C in precancerous lesions and its principal suspected harm, thyroid disturbance.

Mechanism of Action

Indole-3-carbinol does not exist in intact plants: damaging cabbage-family tissue lets the enzyme myrosinase cleave the storage compound glucobrassicin, releasing it. I3C is unstable, condensing in stomach acid within minutes into a mixture dominated by 3,3’-diindolylmethane (DIM, the compound that reaches the bloodstream), alongside indolo[3,2-b]carbazole and oligomers.

Two switches carry most of the biology. The first is the aryl hydrocarbon receptor (AhR, a protein sensor that switches on genes for clearing foreign chemicals). Several condensation products bind it, inducing the cytochrome P450 enzymes CYP1A1, CYP1A2 and CYP1B1 (enzymes that oxidize drugs, toxins and hormones). Induced CYP1A2 pushes estradiol down the 2-hydroxylation route, raising 2-hydroxyestrone (a weakly active breakdown product) relative to 16α-hydroxyestrone (a more strongly active one). The same induction reads two ways: CYP1A1 and CYP1B1 also activate some procarcinogens, and sustained AhR signaling is itself tumor-promoting, the competing account behind the rodent promotion findings. The second is Nrf2 (a master regulator of the cell’s detoxification genes), whose activation raises glutathione S-transferase and other enzymes that tag reactive compounds for excretion.

Independent of both, DIM antagonizes the androgen receptor, and I3C inhibits WWP1 (the enzyme that tags the tumor suppressor PTEN for disposal), reactivating PTEN in cells.

Pharmacologically, I3C itself is undetectable in plasma. DIM is fat-soluble and distributes into liver and fatty tissue; it peaks about two hours after an oral dose and falls below detection by 24 hours, so exposure is short. Clearance is by cytochrome P450 hydroxylation then sulfate and glucuronide conjugation, with wide person-to-person variation.

Historical Context & Evolution

I3C was not developed as a therapy. It was identified in the 1970s and 1980s as one of the compounds behind the anti-carcinogenic activity of cabbage-family vegetables in rodent bioassays, where it blocked tumors initiated by aflatoxin and nitrosamines. Its original use was as a laboratory probe, not a supplement.

The move toward human use came from hormone research. Work at the Institute for Hormone Research in New York in the late 1980s and early 1990s showed that oral I3C shifted estradiol metabolism toward 2-hydroxylation in healthy volunteers (Michnovicz & Bradlow, 1991), and that the shift persisted over three months (Bradlow et al., 1994). Because a high ratio of 2-hydroxyestrone to 16α-hydroxyestrone had been associated with lower breast cancer risk in observational work, the compound was adopted as a candidate chemopreventive agent and entered dose-ranging and phase I trials.

The picture complicated in parallel. Several rodent studies found that the same compound promoted rather than prevented tumor development when it was given after the initiating carcinogen instead of before it, with increased liver foci and thyroid tumors reported in a rat multi-organ model (Kim et al., 1997). This was never resolved. The promotion findings are real and reproducible in their own protocols; whether the timing dependence they demonstrate applies at human supplement doses has not been tested in people. Later trials in cervical, vulvar and airway lesions produced mixed results, and attention shifted toward DIM as a more stable alternative, leaving the underlying question unanswered.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence consists of single small randomized trials with histologic endpoints and uncontrolled open-label series, with no clinical-endpoint finding replicated in more than one trial.

Medium 🟩 🟩

Regression of Precancerous Cervical Lesions ⚠️ Conflicted

A 12-week placebo-controlled randomized controlled trial (RCT, a study assigning participants to treatment or control by chance) in 30 women with high-grade cervical intraepithelial neoplasia (CIN, precancerous change in the cervical lining) reported complete histologic regression on repeat biopsy. Larger later trials of the metabolite DIM found no advantage over placebo, while a Russian trial of vaginal DIM suppositories reported large effects against a high placebo response. Net reading: one small positive oral I3C trial stands unreplicated, and oral DIM has not confirmed it.

Magnitude: Complete regression in 4 of 8 women at 200 mg/day and 4 of 9 at 400 mg/day versus 0 of 10 on placebo; relative risk (the chance of an outcome on treatment divided by the chance on placebo) of persisting disease 0.50 (95% confidence interval (CI, the range within which the true value probably lies) 0.25–0.99) and 0.55 (CI 0.31–0.99) respectively (Bell et al., 2000). The negative DIM comparison reported CIN 2 or worse in 9% versus 12% (Castañon et al., 2012).

Low 🟩

Symptom and Lesion Improvement in Vulvar Intraepithelial Neoplasia ⚠️ Conflicted

A randomized dose-comparison trial in vulvar intraepithelial neoplasia (a precancerous vulvar skin change) had no placebo arm; itch, pain, lesion size and appearance improved, but biopsy showed no change in tissue grade. The 2025 meta-analysis classes I3C as ineffective. Net reading: symptom relief is uncontrolled and the disease was unaltered.

Magnitude: Direction is toward improvement in itch (P = 0.018, the probability that a difference this large arose by chance), pain (P = 0.028), lesion size (P = 0.005) and appearance (P = 0.046) over six months in 12 women taking 200–400 mg/day, with tissue grade unchanged (P = 0.317); the trial reports no outcome figure for the symptom or lesion scores (Naik et al., 2006).

Remission of Recurrent Respiratory Papillomatosis

In recurrent respiratory papillomatosis (RRP, repeated wart-like growths in the airway driven by human papillomavirus), an open-label series treated patients for a mean of 4.8 years after surgical clearance. A third stopped needing further surgery. Uncontrolled, with no placebo arm, in a condition whose natural course varies widely.

Magnitude: 11 of 33 patients (33%) had complete remission and required no further surgery, 10 (30%) needed less frequent surgery, and 12 (36%) did not respond; no patient worsened (Rosen & Bryson, 2004).

Reduction in Lupus Disease Activity

An open-label study in premenopausal women with systemic lupus erythematosus (SLE, an autoimmune disease in which the immune system attacks the body’s own tissues) tracked disease activity for three months. Scores fell then partly rebounded after withdrawal, but the change was not statistically significant and the study was uncontrolled.

Magnitude: Mean score on the SLE Disease Activity Index (a validated scale rating lupus severity) moved from 10.0 at baseline to 6.25 at three months and 8.8 three months after stopping; the difference was not statistically significant (McAlindon et al., 2001).

Improvement in Benign Prostatic Hyperplasia Symptoms

A systematic review reports reduced symptom severity and improved urinary flow with a marketed I3C preparation in benign prostatic hyperplasia (BPH, age-related prostate enlargement). Evidence is indirect: the product also contains a green-tea catechin, so I3C’s own contribution cannot be separated, and the authors work for the manufacturer.

Magnitude: Direction is toward reduced symptom severity and improved urinary-flow measures with continued use; the review reports no pooled effect size for the I3C component alone (Sokolov & Tsareva, 2026).

Speculative 🟨

Shift of Estrogen Metabolism Toward the 2-Hydroxy Pathway

Replicated in controlled human trials: the urinary 2-hydroxyestrone to 16α-hydroxyestrone ratio rose about 66% at 400 mg/day, with no further gain at 800 mg (Reed et al., 2005). The ratio remains an unvalidated surrogate.

Induction of Phase II Detoxification Enzymes

Lymphocyte glutathione S-transferase activity (an enzyme that tags reactive compounds for excretion) rose 69% on 800 mg/day in a phase I trial (Reed et al., 2005). An enzyme-activity biomarker, with no linked human outcome.

Clearance of Senescent Cells

In mouse and human fibroblasts, I3C raised senescence (cells that stop dividing but persist) early, then cut senescent-cell numbers by triggering programmed cell death (Sax et al., 2024). Cell-culture only; no animal or human confirmation.

Reactivation of the PTEN Tumor Suppressor

I3C inhibits WWP1, the enzyme that disables PTEN, restoring its tumor-suppressing activity in cells and in mice (Lee et al., 2019). Mechanistic and preclinical only, at concentrations well above human plasma levels.

Extension of Lifespan in an Autoimmune Mouse Model

Autoimmune-prone mice fed I3C from weaning showed 80% survival at twelve months versus 10% of controls, with less severe kidney disease (Auborn et al., 2003). A single disease-model animal study; no human lifespan data exist.

Benefit-Modifying Factors

  • CYP1A2 activity and the CYP1A2*1F variant: CYP1A2 is the liver enzyme that performs estrogen 2-hydroxylation. Carriers of the rapid-inducer variant may show a larger metabolic shift on the same dose, while low-activity individuals respond less.

  • Baseline estrogen metabolite ratio: The size of the response is inversely related to the starting 2-hydroxyestrone to 16α-hydroxyestrone ratio. Those already high on the measure gain little; those lowest at baseline showed the largest shifts in dose-ranging work.

  • Non-responder status: Roughly 3 of 20 women in a three-month trial showed no change in the metabolite ratio at any timepoint despite adherence (Bradlow et al., 1994), indicating a genuine non-responding subgroup that gains nothing from continued use.

  • Sex: The estrogen 2-hydroxylation response was equal in men and women in the earliest controlled work (Michnovicz & Bradlow, 1991). Androgen-receptor antagonism by the metabolite, by contrast, is relevant mainly to men and may reduce free androgen availability.

  • Adiposity: Obese premenopausal women, whose estrogen metabolism is shifted toward the more active pathway at baseline, still showed the expected metabolic response, so raised body fat does not appear to block the effect.

  • Pre-existing hormone-sensitive conditions: Endometriosis, uterine fibroids and estrogen-receptor-positive breast cancer are the settings where a shift in estrogen handling is most likely to matter clinically, and where trials have concentrated.

  • Age: Most trial participants were premenopausal. After menopause, ovarian estradiol output is low and the metabolic shift has far less substrate to act on, so the main proposed benefit likely attenuates with age.

  • Gastric acidity: Conversion of I3C to its active condensation products requires stomach acid. Acid-suppressing medication, atrophic gastritis (thinning of the stomach lining that lowers acid output) or taking the capsule apart from food plausibly reduces metabolite yield.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Induction of CYP1A2 and Faster Clearance of Co-administered Drugs

CYP1A2 (a liver enzyme that breaks down a defined set of medications, including clozapine, olanzapine, theophylline, tizanidine, duloxetine and melatonin) is strongly induced by I3C. In a phase I trial using caffeine as a probe, activity rose in 94% of participants. An earlier controlled study of estradiol 2-hydroxylation showed the same induction in men and women at supplement-range doses. Faster clearance lowers plasma levels of substrate drugs, which for narrow-therapeutic-index agents can mean loss of therapeutic effect.

Magnitude: Mean 4.1-fold increase in CYP1A2 activity at 800 mg/day, present in 94% of 17 participants (Reed et al., 2005); roughly 50% increase in estradiol 2-hydroxylation at 6–7 mg/kg/day over one week (Michnovicz & Bradlow, 1991).

Medium 🟥 🟥

Reduced Plasma Levels of Tamoxifen’s Active Metabolites

In a 12-month RCT in women taking tamoxifen, the metabolite DIM significantly lowered plasma endoxifen, 4-hydroxytamoxifen and N-desmethyl-tamoxifen. Endoxifen is the metabolite that carries most of tamoxifen’s anti-estrogen activity, and its concentration is the accepted measure of adequate tamoxifen exposure. The trial authors flagged the possibility that this attenuates tamoxifen’s clinical benefit. Evidence is from a single trial of DIM, not I3C, though I3C is converted to DIM in the stomach.

Magnitude: Direction is toward lower plasma endoxifen, 4-hydroxytamoxifen and N-desmethyl-tamoxifen, appearing by six weeks and holding for the remaining year, across the 47 women who completed 150 mg DIM twice daily against 51 on placebo (each reduction P ≤ 0.001), with more women falling below the proposed 5.6 ng/mL endoxifen threshold; the trial reports no outcome figure for the size of the reduction (Thomson et al., 2017).

Treatment-Emergent Adverse Events ⚠️ Conflicted

Reported tolerability diverges sharply by trial. A placebo-controlled trial of vaginal DIM found adverse events roughly twice as frequent on active treatment as on placebo, though none were serious. Two oral trials reported the compound as well tolerated, with nausea in a small minority and no toxicity on blood counts or liver panels. A year-long trial found only one effect differing from placebo: visibly discolored urine, benign but common. Net reading: adverse events are common but mild, more visible in trials that actively solicited them.

Magnitude: Adverse events in 40.0% (100 mg/day) and 42.0% (200 mg/day) versus 22% on placebo, none serious (Ashrafian et al., 2015); grade 2 nausea in 2 of 64 participants with normal blood counts and liver panels throughout (Del Priore et al., 2010); discolored urine in 40% over 12 months, the only adverse event differing from placebo (Thomson et al., 2017).

Increased Sex Hormone-Binding Globulin

Sex hormone-binding globulin (SHBG, a blood protein that binds testosterone and estradiol and limits how much is biologically available) rose substantially on the metabolite in a year-long RCT. In women being treated for breast cancer this was presented as favorable. For a man using the compound, the same change reduces free testosterone at a given total level, and adds to the androgen-receptor antagonism the metabolite exerts directly.

Magnitude: SHBG rose 25 ± 22 nmol/L on 150 mg DIM twice daily versus 1.1 ± 19 nmol/L on placebo over 12 months (Thomson et al., 2017).

Ineffectiveness Leading to Delayed Definitive Treatment

The clearest harm signal in the clinical record is failure. The 2025 meta-analysis of vulvar lesion treatments classed I3C as ineffective, and the largest DIM trial in cervical abnormalities found no effect on cytology or viral clearance. In lesions with malignant potential, months spent on an ineffective agent postpone treatments with established response rates.

Magnitude: No sign of disease at six months in 27.3% on DIM versus 34.3% on placebo, relative risk 0.8 (CI 0.6–1.0), across 551 randomized women (Castañon et al., 2012); I3C classed as ineffective for vulvar lesions (Simões et al., 2025).

Low 🟥

Thyroid Function Disturbance ⚠️ Conflicted

Cabbage-family compounds are long suspected of suppressing thyroid function, and a rat model found I3C increased thyroid tumors. A 2024 systematic review of 123 studies found human dietary data do not support an antithyroid effect where iodine is adequate. Net reading: no human signal, untested at supplement doses.

Magnitude: Direction is no measurable change in thyroid hormones in humans provided iodine intake is adequate; the review reports no outcome figure for supplement-dose I3C (Galanty et al., 2024).

Reduced FMO3 Activity and Body Odor

FMO3 (flavin-containing monooxygenase 3, the enzyme that turns a fishy-smelling gut compound into an odorless oxide) is competitively inhibited by I3C condensation products. A controlled human feeding study showed cabbage-family vegetables reduced its activity. Most relevant to people with partial FMO3 deficiency.

Magnitude: Urinary trimethylamine to trimethylamine N-oxide ratio rose 2.6- to 3.2-fold on 300 g/day of cooked Brussels sprouts for three weeks; the inhibition was traced in vitro to I3C condensation products (Cashman et al., 1999).

Effects on Clotting ⚠️ Conflicted

I3C inhibited collagen-induced platelet aggregation and protected mice from experimental thrombosis, pointing toward bleeding. Human experience points the other way: isolated case reports link the metabolite DIM to deep vein thrombosis, pulmonary embolism and ischemic stroke. Net reading: the direction in people is unsettled.

Magnitude: Not quantified in available studies. No controlled trial has reported a bleeding or clotting event in either direction; the human record is two case reports (Bui et al., 2016; Pence et al., 2023) set against laboratory and mouse antiplatelet data (Park et al., 2008).

Balance Disturbance and Tremor at High Doses

Balance disturbance and tremor were reported at 800 mg/day during long-term airway papillomatosis treatment and resolved when the dose was lowered (Rosen et al., 1998). A skin rash at 375 mg/day (McAlindon et al., 2001) and slight liver-enzyme rises are the other human reports. All are uncontrolled observations.

Magnitude: Direction is toward balance disturbance and tremor appearing only at the top of the dose range and reversing on dose reduction; the reports give no incidence figure (Rosen et al., 1998).

Speculative 🟨

Tumor Development Without a Prior Carcinogen

A two-year gavage bioassay found liver tumors in male mice and uterine cancers in female rats given I3C alone (National Toxicology Program, 2017). Animal only, at doses far above human use.

Tumor Promotion When Given After Carcinogen Exposure

In a rat multi-organ model, dietary I3C given during the promotion phase increased precancerous liver lesions and thyroid tumor incidence (Kim et al., 1997). Animal only; the timing dependence has never been tested in humans.

Hepatocellular Hypertrophy and Broad P450 Induction

Oral I3C at 50 mg/kg/day for 28 days enlarged rat livers and induced multiple P450 enzymes, fully reversing after withdrawal; DIM did neither (Crowell et al., 2006). Animal only, at doses far above human use.

Risk-Modifying Factors

  • FMO3 variants: FMO3 converts trimethylamine to an odorless oxide. Carriers of reduced-function variants, common enough to cause mild odor complaints, are the people in whom inhibition by I3C is most likely to become noticeable.

  • CYP1A2 genotype and smoking status: CYP1A2 clears several psychiatric and respiratory drugs. Smokers already have induced activity; adding I3C compounds the induction and can push substrate drug levels below the effective range.

  • CYP2D6 metabolizer status: CYP2D6 converts tamoxifen into its active metabolite. Poor or intermediate metabolizers already have low endoxifen, so any further reduction from I3C or its metabolite matters disproportionately to them.

  • Baseline liver enzymes and iodine status: Raised transaminases before starting leave less margin for the enzyme induction seen in animals, and low iodine intake is the condition under which cabbage-family compounds have shown thyroid effects.

  • Sex: Androgen-receptor antagonism and the rise in sex hormone-binding globulin make reduced free testosterone a male-specific concern. The estrogen-lowering effects that are sought by women are the same effects men may not want.

  • Pre-existing conditions: Hypothyroidism, chronic liver disease, bleeding disorders and hormone-receptor-positive cancers under active treatment are the settings where the identified risks have the most room to become clinically relevant.

  • Age: Older adults take more medications at once, so the drug-clearance interaction is the dominant risk at the older end of the target range, and age-related decline in stomach acid alters how much active metabolite is formed.

Key Interactions & Contraindications

  • Tamoxifen (caution, monitor): Lowers plasma endoxifen and other active metabolites, potentially reducing anti-cancer effect. Mitigation: avoidance of concurrent use, or endoxifen level measurement where use is unavoidable.

  • CYP1A2 substrate antipsychotics (clozapine, olanzapine) — caution: Induction lowers plasma levels and can precipitate relapse. Mitigation: therapeutic drug monitoring, prescriber-led dose adjustment, and no abrupt starts or stops.

  • Theophylline and tizanidine (caution): Both are narrow-therapeutic-index CYP1A2 substrates. Induction reduces efficacy; an abrupt stop then lets levels rebound toward toxicity. Mitigation: level monitoring, with one variable changed at a time.

  • Warfarin and direct oral anticoagulants (apixaban, rivaroxaban) — monitor: Enzyme induction plus a laboratory antiplatelet effect gives an unpredictable net direction. Mitigation: more frequent international normalized ratio checks after starting or stopping.

  • Melatonin (minor): Melatonin is cleared by CYP1A2, so induction shortens its exposure and may blunt a sleep-timing effect. Mitigation: timing separation does not help; a melatonin dose increase is the practical response.

  • Caffeine (minor): Cleared by the same enzyme, so habitual caffeine effects weaken as clearance accelerates. Mitigation: none required beyond anticipating the change.

  • Acid-suppressing medication — proton pump inhibitors (omeprazole), H2 blockers (famotidine) — caution: Raising gastric pH reduces the acid condensation that generates the active metabolite, so the supplement may not work. Mitigation: substitution of a pre-formed DIM product.

  • Sulforaphane and broccoli sprout extracts (caution, additive): Both act on the same detoxification switches, so enzyme induction is additive rather than independent. Mitigation: accounting for total cruciferous load rather than treating each as a separate input.

  • Green tea catechins (caution, additive): Co-formulated with I3C in marketed products; the combination adds further enzyme modulation and its own liver-injury signal at high extract doses. Mitigation: single-ingredient products.

  • Estrogen therapy and combined oral contraceptives (estradiol, ethinylestradiol) — caution: I3C accelerates estradiol clearance, which can reduce the intended hormonal effect. Mitigation: symptom monitoring; the interaction is not a reliable contraceptive effect.

  • Fish oil, vitamin E, garlic and other antiplatelet supplements (caution): Additive effects on platelet aggregation in laboratory models. Mitigation: discontinuation of the stack 7–10 days before any surgery.

Populations who should avoid Indole-3-Carbinol:

  • Pregnant or breastfeeding women — no human safety data, and the compound crosses into fetal tissue in animal studies
  • Anyone taking tamoxifen for breast cancer treatment or prevention
  • People with a hormone-receptor-positive cancer under active endocrine treatment
  • People on clozapine, olanzapine, theophylline or tizanidine without therapeutic drug monitoring
  • People with untreated hypothyroidism or a thyroid-stimulating hormone above 4.0 mIU/L
  • People with active liver disease or transaminases above twice the upper limit of normal
  • People with a diagnosed bleeding disorder, or within 10 days of planned surgery
  • Children and adolescents outside a supervised trial protocol

Risk Mitigation Strategies

  • Medication review before the first dose: A screen of the full medication list for CYP1A2 substrates and tamoxifen addresses the two interactions with documented human consequences, before rather than after a problem appears.

  • Starting at 200 mg/day for four weeks: Dose-ranging data place the minimum effective dose near 300 mg/day and the ceiling near 400 mg/day (Wong et al., 1997), so a low start limits early gastrointestinal upset.

  • Ceiling of 400 mg/day: Enzyme induction and the estrogen metabolite shift both plateau at 400 mg/day, while systemic exposure keeps climbing to 1,000 mg. Higher doses add risk without adding effect.

  • Baseline and 12-week liver panel: Addresses the reversible hepatocyte hypertrophy and P450 induction seen in rats, catching any human counterpart while it is still an enzyme change rather than injury.

  • Thyroid panel at baseline and 6 months, with adequate iodine intake: The systematic review found no thyroid effect specifically where iodine intake was sufficient, making iodine adequacy the condition under which that reassurance applies.

  • A fixed decision point at 3–6 months: Addresses the delayed-treatment risk. Where a measurable lesion or symptom motivated use and has not changed by then, the agent has failed on its own terms.

  • Staged reduction rather than abrupt stop on substrate drugs: Sudden withdrawal lets induced CYP1A2 activity fall back over roughly a week, raising substrate drug levels toward toxicity. A two-week taper with monitoring avoids the rebound.

  • Withdrawal 10 days before surgery or dental extraction: Covers the laboratory antiplatelet effect, which has no human bleeding data either way and is therefore best removed from the picture around procedures.

Therapeutic Protocol

  • Standard dose: 200–400 mg/day of I3C, taken orally. The dose-ranging trial placed the minimum effective dose at 300 mg/day (Wong et al., 1997); phase I work found no further gain above 400 mg/day.

  • Conventional oncology approach: Trial protocols used 200 or 400 mg/day for 12 weeks in cervical lesions and 200 mg twice daily long-term in airway papillomatosis, in both cases after surgical clearance rather than instead of it.

  • Integrative practitioner approach: Functional-medicine protocols favor DIM at 100–200 mg/day over I3C, arguing the metabolite is more stable and dosing more predictable. Neither approach has outperformed the other in a head-to-head trial.

  • Originating clinics: The Strang Cancer Prevention Center and the Institute for Hormone Research in New York established the oral dose range; the University of Pittsburgh Voice Center developed the long-term airway protocol.

  • Timing: Administered with food. Stomach acid drives the condensation that produces the absorbable metabolite, so an empty stomach or concurrent acid suppression reduces yield.

  • Time of day: No circadian dependence has been established. Morning dosing with breakfast is conventional and keeps the absorption peak away from bedtime.

  • Half-life: The parent compound is never detectable in plasma. Its metabolite peaks at about two hours and falls to the limit of quantitation by 24 hours, indicating a short effective exposure window.

  • Split versus single dose: Twice-daily dosing suits the short metabolite exposure and was used in the long-term airway protocol; single daily dosing was used in the cervical and breast trials and achieved the full metabolic shift.

  • Genetic considerations: CYP1A2 and CYP2D6 status shape both response and interaction risk. Fast CYP1A2 inducers reach the metabolic plateau at lower doses; CYP2D6 poor metabolizers on tamoxifen fall under the avoid list rather than a dose adjustment.

  • Sex differences: The estrogen-metabolism response is equivalent in men and women. In men, the androgen-receptor antagonism and the rise in sex hormone-binding globulin argue for the lower end of the dose range.

  • Age: Trial participants were overwhelmingly premenopausal. Beyond the sixth decade, lower ovarian estradiol output and reduced gastric acid both shrink the expected effect, while multiple concurrent medications raise interaction risk.

  • Baseline biomarkers: The starting 2-hydroxyestrone to 16α-hydroxyestrone ratio predicts response size inversely, so a low baseline ratio identifies the people most likely to show a measurable shift.

  • Pre-existing conditions: Endometriosis and precancerous cervical or vulvar lesions are the settings with trial protocols to draw on; thyroid disease, liver disease and active endocrine cancer treatment argue against use.

Discontinuation & Cycling

  • Intended duration: Short-to-medium term rather than lifelong. Trial exposures ran 4 to 24 weeks, with the airway papillomatosis protocol the only sustained multi-year use, and that in an active disease.

  • Withdrawal effects: No withdrawal syndrome has been reported. The relevant rebound is pharmacological: induced CYP1A2 activity returns to baseline over roughly a week, raising levels of substrate drugs that were stabilized during use.

  • Effect reversal: The estrogen metabolite shift is not durable. Lupus disease-activity scores drifted back toward baseline within three months of stopping, and the metabolic ratio falls as enzyme induction subsides.

  • Tapering: No taper is needed for the compound itself. A staged reduction over two weeks is worthwhile only for people on narrow-therapeutic-index CYP1A2 substrates, to let drug levels rise gradually under monitoring.

  • Cycling: No trial has tested cycling. The plateau in enzyme induction and metabolite shift by 400 mg/day argues against escalation, and three months on with a reassessment break is the pragmatic pattern in the absence of data.

  • Tolerance: No loss of effect over time has been documented. A sustained metabolic shift held across three months of continuous dosing, with a stable non-responder subgroup rather than fading response.

Sourcing and Quality

  • Stability is the central problem: I3C degrades and self-condenses on exposure to heat, light and moisture, so capsule content can differ from the label after storage. Opaque bottles, desiccant and a dated expiry are the markers of a product likely to hold potency.

  • I3C versus pre-formed DIM: DIM products bypass the acid-conversion step and dose more predictably. Crystalline DIM is poorly absorbed, so absorption-enhanced formulations such as BioResponse DIM are what clinical trials actually used.

  • Third-party testing: Neither compound is covered by a compendial monograph most brands follow, so lot-level certificates of analysis and verification by an independent certification program (NSF, USP or Informed Choice) carry more weight than in-house assay claims.

  • Formulation: Combination products pairing I3C with green tea catechins or additional cruciferous extracts compound the enzyme-induction effects and make attribution of any adverse event impossible; single-ingredient products do not.

  • Reputable sources: Pure Encapsulations, Thorne, Jarrow and Douglas Laboratories supply single-ingredient I3C at trial-relevant doses; compounding pharmacies can supply defined-dose capsules where a specific strength is required.

  • Dose verification: A label stating milligrams of I3C itself is not equivalent to one stating milligrams of a cruciferous extract standardized to a percentage, which can deliver a fraction of the apparent figure.

Practical Considerations

  • Time to effect: The metabolic shift is measurable within one month and plateaus there. Clinical endpoints took longer: cervical lesion trials assessed at 12 weeks, airway and vulvar protocols at 3–6 months.

  • Common pitfall — dose escalation: Exposure keeps rising to 1,000 mg/day while the biological effects plateau at 400 mg. Taking more buys additional enzyme induction and interaction risk without additional benefit.

  • Common pitfall — treating a marker as an outcome: The estrogen metabolite ratio moves reliably and means little on its own. Using it as proof of cancer risk reduction outruns the evidence by a wide margin.

  • Common pitfall — ignoring the medication list: The drug-clearance interaction is the best-documented human effect of the compound, and it is invisible without a deliberate review of what else is being taken.

  • Regulatory status: Sold as a dietary supplement in the United States and European Union, with no approved medical indication. In Russia it is marketed as a registered medicine under brand names, which is why several trials originate there.

  • Cost and access: A month at trial doses costs about the price of a basic multivitamin. Insurers and health systems reimburse surgery and licensed topical drugs but not supplements, and the compound is unpatentable, so no party funds the definitive trial.

Interaction with Foundational Habits

  • Sleep: Indirect and potentially blunting. Melatonin is cleared by CYP1A2, which I3C strongly induces, so supplemental melatonin’s exposure shortens. Practical consideration: in people relying on melatonin for sleep timing, the effect weakens, and a melatonin dose adjustment rather than an I3C change is the usual response.

  • Nutrition: Direct and additive. The compound comes from the same glucosinolate pathway as dietary cabbage-family vegetables, so heavy broccoli, kale and Brussels sprout intake adds to the supplement dose. Practical consideration: absorption favors a meal containing fat, iodine adequacy matters, and vegetable intake counts toward total exposure.

  • Exercise: Indirect and potentially blunting for men. The metabolite antagonizes the androgen receptor and raises sex hormone-binding globulin, both of which lower biologically available testosterone. Practical consideration: for men pursuing hypertrophy, the lower end of the dose range applies, and free testosterone rather than total is the informative measure.

  • Stress management: No established interaction. No human study has measured cortisol, the stress response or sleep architecture on I3C, and no mechanism links the aryl hydrocarbon or Nrf2 pathways to the stress axis at supplement doses. Practical consideration: none identified.

Monitoring Protocol & Defining Success

Baseline testing before the first dose covers the systems the compound demonstrably touches: liver enzymes, because rodent work showed reversible liver enlargement and broad enzyme induction; thyroid function, because cabbage-family compounds carry a long-standing thyroid-suppression question; and sex hormones with their binding protein, because that is the axis the compound is taken to alter. A baseline urinary estrogen metabolite ratio serves only as a response check, not as a health measure. The ongoing cadence in trial protocols and functional-medicine practice is a repeat liver and thyroid panel at 12 weeks, then at 6 and 12 months where use continues. Hormone measures are most informative at 12 weeks, once the metabolic shift has plateaued. Where a medication cleared by CYP1A2 is in use, that drug’s own level is checked 2 weeks after starting and again 2 weeks after stopping, since both transitions move it.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–26 U/L (men), 9–22 U/L (women) Detects liver stress from enzyme induction ALT = alanine aminotransferase, an enzyme released when liver cells are damaged. Conventional labs flag only above 40–55 U/L, missing early drift. No fasting needed.
AST 10–26 U/L Confirms an ALT rise is hepatic rather than muscular AST = aspartate aminotransferase. Conventional labs flag only above about 40 U/L. Pair with ALT and creatine kinase; recent hard exercise raises it independently of the liver.
TSH 0.5–2.0 mIU/L Screens for the suspected thyroid-suppressing effect TSH = thyroid-stimulating hormone, the pituitary signal that drives the thyroid. Conventional range extends to 4.5 mIU/L. Draw before 10 a.m.; pair with free T4.
Free T4 1.0–1.5 ng/dL Distinguishes true thyroid suppression from a TSH shift alone T4 = thyroxine, the main thyroid hormone. Best paired with TSH and a urinary iodine check, since the thyroid signal only appears when iodine is low.
Sex hormone-binding globulin 20–60 nmol/L (men), 30–90 nmol/L (women) The documented hormonal change from the metabolite Binds testosterone and estradiol, limiting how much is biologically available. Fasting morning draw; interpret alongside total testosterone.
Free testosterone 15–25 pg/mL (men) Captures the net androgen effect that binding-protein changes cause Calculated free testosterone is more reliable than direct assay. Morning draw before 10 a.m.; total testosterone alone will miss the change.
Urinary 2-hydroxyestrone : 16α-hydroxyestrone ratio No established target; track change from the individual’s own baseline, with a doubling indicating a full response Confirms the compound is being converted and absorbed at all First-morning void. This is a response check, not a health outcome; the ratio is not a validated surrogate for cancer risk.
Plasma level of any CYP1A2-substrate medication No supplement-specific target; keep within that drug’s own established therapeutic range The only interaction with documented human consequences Applies to clozapine, olanzapine, theophylline, tizanidine and duloxetine. Check 2 weeks after starting and 2 weeks after stopping, since levels move in both directions.

Qualitative markers worth tracking alongside the laboratory measures:

  • Cyclical breast tenderness and menstrual symptom severity, which are the changes women most often report first
  • Libido and morning erections in men, as the practical readout of reduced free androgen
  • Body odor, specifically a fishy character, which signals the enzyme inhibition that affects odor handling
  • Gastrointestinal comfort in the first four weeks, the window in which nausea appeared in trials
  • Energy and cognitive clarity, which shift when caffeine and melatonin are cleared faster than before
  • For anyone using it against a visible lesion, the symptom score that motivated use, reassessed against a fixed decision point

Emerging Research

  • Endometriosis head-to-head trial: NCT07164183 randomizes 290 women to I3C 200 mg twice daily or dienogest 2 mg for 24 weeks, with daily pelvic pain score as the primary endpoint. The first phase 3 non-inferiority test of I3C against an approved drug. Recruiting, completing late 2026.

  • Lung chemoprevention in smokers: NCT03687073 gave I3C with silibinin to 21 smokers at the University of Minnesota, a phase 1 study of safety, pharmacokinetics and inflammatory markers. Completed 2021 with no results posted; its dosing and exposure data are what a chemoprevention trial in smokers would be built on.

  • Carcinogen pharmacokinetics under dietary modification: NCT03802721 at Oregon State University tracked benzo[a]pyrene handling under altered diet in 7 participants, completed 2024. Directly tests the mechanism that underpins the whole chemoprevention case.

  • Breast cancer susceptibility protein: NCT01022333 proposed testing whether DIM raises BRCA1 protein output in carriers of the mutation. Registry status is unknown and no results have been posted, which itself indicates how thin the pipeline has become.

  • Senescent-cell clearance follow-up: The finding that I3C clears senescent cells by triggering programmed cell death (Sax et al., 2024) is the most direct longevity claim yet made for the compound. It has no animal or human confirmation, and would strengthen the case substantially if reproduced in living animals.

  • Tumor-suppressor reactivation: The demonstration that I3C inhibits WWP1 to restore PTEN activity (Lee et al., 2019) supplied a plausible mechanism independent of hormones, but at concentrations far above human plasma levels. Bioavailability work will determine whether it is reachable.

  • Evidence that could weaken the case: Replication of the rat promotion finding (Kim et al., 1997) in a second species, or any trial confirming that reduced tamoxifen metabolite levels (Thomson et al., 2017) translate into worse cancer outcomes, would move the balance decisively against use.

Conclusion

Indole-3-carbinol comes from cabbage-family vegetables, is unstable in the stomach, and acts through the products it becomes there. Its most reliable effects in people are a change in the route by which estrogen is broken down, and strong activation of a liver enzyme system that also clears a defined set of medications.

The case for benefit rests thinner than its popularity suggests. One small randomized trial found precancerous cervical lesions regressing; a later, larger trial of the breakdown product it forms in the stomach did not confirm it, and a recent pooled review of vulvar lesion treatments classed the compound as ineffective. Airway and lupus findings come from studies with no comparison group. The laboratory marker that moves consistently has never been shown to predict disease outcomes. Longevity claims rest entirely on cell and mouse work.

Against this, the drug-clearance effect is the best-documented human finding of all, and it is a liability rather than a benefit. A year-long trial found reduced levels of an active breast cancer drug, and animal work in which the compound itself raised tumor rates — both after a cancer-causing chemical and on its own over two years — has never been resolved.

The evidence base is small, old and partly produced by companies selling the product, including the only review covering men’s health and the review that compared the compound against that breakdown product. The compound is cheap and cannot be owned, so no commercial party has a financial stake in its study.

Top - Benefits - Risks - Protocol